photonamic GmbH and Co. KG, a subsidiary company of medac GmbH, was founded in 2002 with the objective of developing 5-aminolevulinic acid in the field of fluorescence diagnosis and photodynamic therapy.
photonamic’s research and development work for 5-aminolevulinic acid and other photosensitisers cover both therapeutic and diagnostic approaches in the areas of oncology, dermatology and other indications. One of the key aspects of our current activities is the antimicrobial photodynamic therapy.
With Gliolan®, photonamic - in cooperation with its parent company – developed a drug for the intraoperative visualisation of malignant brain tumors ( glioblastoma, WHO grade III-IV). Gliolan® was first approved in Europe in 2007 (via a centralised procedure) and it is marketed by medac in Europe, Africa, South America, and Asia with the exception of Japan and Korea. In the USA, Canada, Australia, New Zealand, Japan and Korea, photonamic collaborates with other partners.
In the field of dermatology, photonamic has developed Alacare, a 5-aminolevulinic acid containing patch with integrated light protection for the photodynamic treatment of mild actinic keratoses. Alacare was approved in Europe in 2009 via a decentralised procedure.
As a development company, photonamic aims to license out its products to qualified partners for marketing and distribution.
In addition, photonamic co-operates closely with companies working in the field of fluorescence diagnosis and photodynamic therapy. This provides access to both light sources and light delivery systems and to new photosensitiser compounds.
